Evaluating serum CXCL12, sCD22, Lp-PLA2 levels and ratios as biomarkers for diagnosis of Alzheimer's disease

Table 1 General information of patients

Feature	AD group (n = 60)	Control group (n = 60)	P value
Age (yr)	73.5 ± 6.2	72.8 ± 5.9	0.452
Gender (male/female)	28/32	30/30	0.743
Years of education	11.4 ± 2.3	11.8 ± 2.1	0.321

AD: Alzheimer's disease.

Table 2 Serum marker levels

Serum indicators	AD group (n = 60)	Control group (n = 60)	P value
CXCL12 (ng/mL)	47.2 ± 8.5	32.8 ± 5.7	< 0.001
sCD22 (ng/mL)	14.3 ± 2.1	18.9 ± 3.4	< 0.01
Lp-PLA2 (ng/mL)	112.5 ± 20.6	89.7 ± 15.2	< 0.05

AD: Alzheimer's disease.

Table 3 Ratio analysis

Ratio indicator	AD group (n = 60)	Control group (n = 60)	P value
CXCL12/sCD22	3.3 ± 0.6	1.7 ± 0.4	< 0.001
Lp-PLA2/sCD22	8.0 ± 1.2	5.2 ± 0.9	< 0.05

AD: Alzheimer's disease.

Table 4 Receiver operating characteristic curve analysis

Test result variable	AUC	Standard error	95%CI
CXCL12	0.787	0.043	0.702-0.871
sCD22	0.713	0.047	0.621-0.804
LpPLA2	0.648	0.051	0.548-0.747
CXCL12sCD22	0.682	0.049	0.586-0.779
LpPLA2sCD22	0.568	0.054	0.463-0.672

AUC: Area under the curve.